Saxenda® provides consistent weight loss and improvements in blood glucose control across BMI categories after three years of treatment

Munich, Germany, 14 September 2016 - Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show that people treated with Saxenda^® (liraglutide 3 mg) experienced consistent weight loss and improved blood glucose control across baseline body mass index (BMI) categories over three years as compared to placebo treatment. These data were presented today at the 52^nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.

Further information

Attachment

• Read the full release including references.pdf